Emcure Pharmaceuticals Ltd

Stage 2 · Advancing · week 43Setup 6.3 ★ FairStrong +7.2

As of 9 Oct 2026, Emcure Pharmaceuticals is in Stage 2 — advancing, the uptrend phase, in week 43 (since 8 Dec 2025). It closed at ₹1,834, 8.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. More about the company

₹1,833.5
-0.97% today
₹34,783 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.3 ★ Fair

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #19 of 61 in Pharmaceuticals · #21 of 78 in Health Care

Is EMCURE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-8.8%
₹1,279.9 lo₹2,009.6 hi
8.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 43
1w13w26w
Week 43 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
8.2%
200 DMA: ₹1,694.7 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.36x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.9% vs MA50 +2.1%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.8%
3M
+1.1%
6M
+17.1%
YTD
+32.9%
1Y
+44.2%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #20 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #17 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2024-07-10 → 2026-10-09
S? 43w
S2 13w
S2 44w
2024-07-102026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S4 2w → S1 7w → S2 13w → S3 7w → S2 44w current
Total tracked: 117 weeks across 6 stage runs.
Scan Membership
Breakout Watch
Latest: 2025-12-08
2 appearances in last 60 days. First seen: 2025-07-14.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 43 · Vol 0.36x
2026-10-08S2
Wk 43 · Vol 0.38x
2026-10-07S2
Wk 43 · Vol 0.22x
2026-10-06S2
Wk 43 · Vol 2.25x
2026-10-05S2
Wk 42 · Vol 0.40x
2026-10-01S2
Wk 42 · Vol 0.41x
2026-09-30S2
Wk 42 · Vol 0.41x
2026-09-29S2
Wk 42 · Vol 1.94x
2026-09-28S2
Wk 42 · Vol 0.22x
2026-09-25S2
Wk 41 · Vol 0.18x
2026-09-24S2
Wk 41 · Vol 0.27x
2026-09-23S2
Wk 41 · Vol 0.21x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,926.3
200 DMA
₹1,694.7
52W High
₹2,009.6
52W Low
₹1,279.9
5D Low
₹1,833.5
Resistance levels (recent highs)
20d High
₹2,003.8
60d High
₹2,009.6
120d High
₹2,009.6
250d High
₹2,009.6
Next resistance
+9.3%
to 20d High
Ask the Market AI about EMCUREAsk →
P/E (TTM)
35.4
Forward 23.2
Earnings Growth (YoY)
+28.8%
Revenue +16.7%
ROE
+19.6%
Profit margin +10.0%
Dividend Yield
0.18%
P/B 6.6
About this companyHealth Care· Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.